Finally, we identified several compounds—such as norcantharidin and naringenin—with high binding affinity to PPP1CA and CTSD, providing valuable evidence for clinical treatment and drug development in T2DM. The gene discussed is CTSD; the disease is type 2 diabetes mellitus.